.jpeg)
{{ variable.name }}
Trelagliptin Succinate can delay the degradation of endogenous glucagon-like peptide-1 (GLP-1), thereby increasing the plasma concentration of active GLP-1.
1. Trade name: Zafatek(ザファテック)
2. Common name: TrelagliptinS uccinate (trotagliptin succinate)
It is used for the treatment of type 2 diabetes as an auxiliary treatment to diet therapy and exercise therapy. It is used when these basic treatment measures are ineffective.
1. Specifications : 100mg
2. Properties : There is a dose mark printed on the surface of the tablet, and the content is white to off-white powder
1. Active ingredients: Trelagliptin Succinate (Trelagliptin Succinate)
2. Additives: Including D-mannitol, crystalline cellulose, croscarmellose sodium, hydroxypropyl cellulose, sodium stearyl fumarate, hypromellose, polyethylene glycol 6000, titanium oxide, ferric oxide and other excipients.
The usual dosage for adults is 100 mg of trodagliptin (calculated as trodagliptin) orally once a week.
Patients with moderate to severe renal insufficiency need to adjust the dose according to creatinine clearance:
1. Moderate renal insufficiency (Ccr30-50mL/min for men, Ccr25-45mL/min for women): 50 mg per week.
2. Severe renal insufficiency or end-stage renal disease (Ccr<30mL/min for men, Ccr<25mL/min for women): 25 mg per week.
1. Before and after meals: Trolagliptin can be taken with food or on an empty stomach, but it is recommended to take it on the same day every week to keep the blood concentration stable.
2. Missed dose: If you miss a dose, you should take the missed dose immediately when you discover it, and then take it on the same day every week as originally planned.
3. Vomiting: If persistent vomiting occurs after taking it, it is recommended to suspend the medication and consult a doctor.
1. Pregnant and lactating women: Use only when clearly needed and when the benefits of treatment outweigh the potential risks.
Animal experiments show that troagliptin can pass through the placenta and breast milk.
2. Children: No clinical trials have been conducted on children, and the safety and effectiveness are unknown.
3. The elderly: The elderly are often accompanied by decreased renal function, so they should use medications with caution and closely monitor adverse reactions.
Possible adverse reactions include hypoglycemia (the risk increases when combined with other antidiabetic drugs), pemphigoid, acute pancreatitis, intestinal obstruction and other serious adverse reactions, as well as others such as allergic reactions, atrial fibrillation, elevated liver enzymes, etc.
1. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis or pre-diabetic coma.
2. It is contraindicated in patients with severe infection, before and after surgery, and severe trauma.
3. It is forbidden for those who are allergic to the ingredients of trolagliptin.
1. When combined with sulfonylureas, fast-acting insulin secretion-promoting drugs, α-glucosidase inhibitors, biguanides, thiazolidinediones, GLP-1 receptor agonists, and SGLT2 inhibitors, it may enhance the hypoglycemic effect and increase the risk of hypoglycemia, and the dose needs to be adjusted.
2. When used in combination with insulin, beta-blockers, salicylic acid preparations, monoamine oxidase inhibitors, fibric acid hyperlipidemia treatment drugs, etc., it may also affect blood sugar levels and requires careful monitoring.
Store unopened medicines at room temperature (below 25°C) and avoid moisture and light.